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Abstract
Germline mutations of the breast cancer 1 (BRCA1) gene are a major cause of familial breast and
ovarian cancer. The BRCA1 protein displays E3 ubiquitin ligase activity, and this enzymatic
function is thought to be required for tumor suppression. To test this hypothesis, we generated
mice that express an enzymatically defective Brca1. We found that this mutant Brca1 prevents
tumor formation to the same degree as does wild-type Brca1 in three different genetically
engineered mouse (GEM) models of cancer. In contrast, a mutation that ablates phosphoprotein
recognition by the BRCA C terminus (BRCT) domains of BRCA1 elicits tumors in each of the
three GEM models. Thus, BRCT phosphoprotein recognition, but not the E3 ligase activity, is
required for BRCA1 tumor suppression.
Germline mutations of the breast cancer 1 (BRCA1) tumor suppressor are a common cause
of hereditary breast and ovarian cancer. The BRCA1 protein harbors an N-terminal RING
motif characteristic of many ubiquitin E3 ligases and two BRCA C terminus (BRCT) motifs
that form a phosphoprotein recognition domain (1-4). BRCA1 interacts with BRCA1-
associated RING domain protein 1 (BARD1) to form a potent E3 ligase (5, 6) that is thought
to regulate multiple pathways, including those responsible for tumor suppression (1-4). To
test whether the E3 ligase activity of BRCA1 is essential for tumor suppression, we
examined mice that express Brca1FH-I26A, an enzymatically defective protein with a
missense mutation (I26A) in the RING domain that allows assembly of the BRCA1/BARD1
heterodimer but abrogates its E3 ligase activity (7, 8). (Single-letter abbreviations for the
amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His;
I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W,
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Trp; and Y, Tyr. In the mutants, other amino acids were substituted at certain locations; for
example, I26A indicates that isoleucine at position 26 was replaced by alanine.)
Brca1FH-I26A/+ and Brca1FH-WT/+ mice were generated from isogenic embryonic stem (ES)
cells that express either Brca1FH-I26A or the corresponding wild-type Brca1FH-WT protein
(9) and bred to homozygosity. Brca1FH-I26A/FH-I26A pups were born at the expected
Mendelian ratio and survived to adulthood. Because Brca1-null mice invariably undergo
embryonic lethality (10, 11), the viability of Brca1FH-I26A/FH-I26A mice indicates that E3
ligase activity is not essential for all BRCA1 functions. Nonetheless, Brca1FH-I26A/FH-I26A,
but not Brca1FH-WT/FH-WT, males are sterile and have smaller testes, and their seminiferous
tubules lack elongated spermatids and spermatozoa (fig. S1), which suggests a block in
spermatogenesis. Apart from male sterility and a modest decrease in adult body weight (5 to
10%), Brca1FH-I26A/FH-I26A mice appear indistinguishable from their Brca1FH-WT/FH-WT
littermates. Moreover, analyses of Brca1FH-I26A/FH-I26A mouse embryonic fibroblasts
(MEFs) revealed that the I26A mutation had no measurable effect on cellular proliferation,
chromosomal stability, senescence induction, centrosome number, spindle formation,
resistance to genotoxic stress, or ubiquitin foci formation at sites of DNA damage—unlike
the hypomorphic Brca1 lesions in MEFs of Brca1tr/tr (12) and Brca1Δ11/Δ11 mice (13),
which are known to disrupt tumor suppression (fig. S2).
To evaluate whether the E3 ligase activity affects tumor suppression, we initially used a
mouse model of pancreatic cancer in which the Pdx1-cre transgene triggers KrasG12D and
p53R172H expression in pancreatic progenitor cells (14). To test whether Brca1 suppresses
formation of these tumors, we generated Pdx1-cre animals carrying KrasLSL-G12D (14)
together with conditional-null Brca1flex2 (15) and/or p53flex7 (16) alleles. Although double-
mutant KrasLSL-G12D/p53flex7/flex7/Pdx1-cre mice succumbed to pancreatic tumors with an
average latency (T50) of 68 days, tumor latency was dramatically reduced in triple-mutant
animals (KrasLSL-G12D/p53flex7/flex7/Brca1flex2/flex2/Pdx1-cre) with conditional-null
Brca1flex2 (T50 = 40 days; P < 0.0001), indicating that wild-type Brca1 suppresses
pancreatic tumor development (Fig. 1A). In contrast, triple-mutant animals (KrasLSL-G12D/
p53flex7/flex7/Brca1flex2/FH-I26A/Pdx1-cre) expressing Brca1FH-I26A developed pancreatic
tumors with a similar latency (T50 = 65 days) as that of double-mutant KrasLSL-G12D/
p53flex7/flex7/Pdx1-cre mice (T50 = 68 days; P = 0.2595) (Fig. 1A). Thus, the tumor
suppression potential of enzymatically inactive Brca1 in the pancreas is indistinguishable
from that of wild-type Brca1.
We next applied a mouse model of familial breast cancer in which the Wapcre gene elicits
mammary-specific inactivation of the conditional-null Brca1flex2 allele (15). However,
unlike Brca1flex2/flex2/Wapcre/+ females, which form tumors resembling the basal-like breast
carcinomas of human BRCA1 mutation carriers (15), all mice expressing enzymatically
inactive Brca1 (Brca1flex2/FH-I26A/Wapcre/+) remained tumor-free over the 24-month
observation period (Fig. 1B).
We also monitored three cohorts of Wapcre/+ mice sensitized for tumor development by a
conditional p53 mutation (p53LSL-R270H). Whereas mammary tumors developed in control
p53LSL-R270H/+/Wapcre/+ females with an average latency of 380 days, which is consistent
with previous studies (17), tumor formation was accelerated (T50 = 308 days) by conditional
Brca1 inactivation in Brca1flex2/flex2/p53LSL-R270H/+/Wapcre/+ females (P < 0.0001) (Fig.
1C). The kinetics of tumor development in Brca1flex2/FH-I26A/p53LSL-R270H/+/Wapcre/+
females was indistinguishable from that of control p53LSL-R270H/+/Wapcre/+ females (P =
0.7502) and significantly slower than that of Brca1flex2/flex2/p53LSL-R270H/+/Wapcre/+
females (P < 0.0001) (Fig. 1C). Moreover, representative oligonucleotide microarray
analysis (18) revealed a “simplex” pattern of genomic copy number variation in
Brca1flex2/FH-I26A/p53flex7/flex7/Wapcre/+ tumors, similar to that of p53flex7/flex7/Wapcre/+
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tumors but distinct from the “complex sawtooth” pattern of Brca1flex2/flex2/p53flex7/flex7/
Wapcre/+ tumors (fig. S3). Thus, mammary-specific loss of Brca1 enzymatic activity does
not promote basal-like breast carcinoma in a manner analogous to complete Brca1
inactivation.
Although mice lacking Brca1 enzymatic activity (Brca1FH-I26A/FH-I26A and Brca1FH-I26A/−)
are viable, some (18.6%) died of tumors at a very advanced age (Fig. 1D). However, the
frequency and kinetics of spontaneous tumor formation in the mutant mice were comparable
with those of Brca1FH-WT/FH-WT control animals (P = 0.5197) and significantly lower than
those of Brca1tr/tr mice (P < 0.0001) (12). Thus, the E3 ligase activity of BRCA1 is
dispensable for tumor suppression in each of the three GEM cancer models.
The BRCT motifs of BRCA1 form a phospho-recognition domain that preferentially binds
the phosphorylated isoforms of repair proteins Abraxas/CCDC98, BACH1/FancJ, and CtIP
(1, 2). Because most tumor-associated BRCA1 alleles have frameshift/nonsense mutations
that eliminate one or both BRCT motifs, BRCT phospho-recognition may be critical for
tumor suppression. Indeed, in some families breast cancer susceptibility can be ascribed to
missense mutations that cause a single amino acid substitution (for example, S1655F) that
disrupts the interaction between the BRCT domain and its cognate phospho-ligands.
Structural studies show that BRCA1 residue S1655 donates a hydrogen bond to the
phosphate group of these phospho-ligands, and that mutation of this residue disrupts their
interaction with BRCA1 (19-23). To determine whether BRCT phospho-recognition is
required for genome stability and tumor suppression, we mutated the corresponding mouse
residue (S1598F) to generate heterozygous (Brca1S1598F/+) and homozygous
(Brca1S1598F/S1598F) ES clones (fig. S4). The Brca1S1598F/+ ES cells were injected into
blastocysts to derive germline chimeras, and heterozygous animals were then intercrossed to
produce homozygous Brca1S1598F/S1598F offspring, which appeared at the expected
Mendelian ratio. Apart from male sterility, these mice developed normally and provided a
source of Brca1S1598F/S1598F MEFs.
The mutant Brca1 protein of Brca1S1598F/S1598F MEFs is expressed at normal levels and
fails to bind Bach1/FancJ (Fig. 2A). Brca1S1598F/S1598F ES cells are hypersensitive to
genotoxic stress (Fig. 2B) and defective for homology-directed DNA repair (Fig. 2C). In
addition, Brca1S1598F/S1598F MEFs display proliferation defects, chromosomal instability,
centrosome amplification, and diminished recruitment of repair proteins to sites of DNA
damage (figs. S5 and S6). Thus, the S1598F mutation disrupts BRCA1 function in the DNA
damage response. To evaluate its effect on tumor suppression, we monitored an
experimental cohort of Brca1flex2/S1598F/p53LSL-R270H/+/Wapcre/+ females and control
cohorts of the p53LSL-R270H/+/Wapcre/+, Brca1flex2/flex2/Wapcre/+, and Brca1flex2/flex2/
p53LSL-R270H/+/Wapcre/+ females described above (Fig. 1, B and C). As shown in Fig. 3A,
mammary tumorigenesis was accelerated in experimental Brca1flex2/S1598F/p53LSL-R270H/+/
Wapcre/+ mice (T50 = 308 days) relative to p53LSL-R270H/+/Wapcre/+ animals (T50 = 380
days; P < 0.0001), and the shortened latency was indistinguishable from that of
Brca1flex2/flex2/p53LSL-R270H/+/Wapcre/+ animals (T50 = 309 days; P = 0.4543). Thus, the
S1598F mutation impairs mammary tumor suppression to a comparable degree as does
complete Brca1 inactivation. Pancreatic tumor formation in mice expressing Brca1S1598F
(KrasLSL-G12D/p53flex7/flex7/Brca1flex2/S1598F/Pdx1-cre; T50 = 45 days) was also accelerated
relative to those expressing wild-type Brca1 (KrasLSL-G12D/p53flex7/flex7/Pdx1-cre mice; T50
= 68 days; P < 0.0001) (Fig. 3B) and comparable with conditional-null Brca1 mice
(KrasLSL-G12D/p53flex7/flex7/Brca1flex2/flex2/Pdx1-cre) (T50 = 40 days; P = 0.2632).
Furthermore, homozygous Brca1S1598F/S1598F mice were highly tumor-prone (49 out of 72;
68.1%) relative to control animals (P < 0.0001) (Fig. 3C). Thus, BRCT phospho-recognition
is critical for BRCA1-mediated tumor suppression in all three GEM cancer models.
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BRCA1 is thought to regulate diverse cellular processes by ubiquitinating multiple protein
substrates (1-4). Indeed, on the basis of the same mutation (I26A) used here the E3 ligase
activity has been implicated in BRCA1 control of centrosome duplication (24), checkpoint
activation (25), mitotic spindle assembly (26), and tumor cell motility (27). In light of these
observations, the viability of mice lacking BRCA1 enzymatic activity was unexpected.
Because mice homozygous for null Brca1 mutations undergo embryonic lethality (10, 11),
our results suggest that the E3 ligase activity of BRCA1 is dispensable for much of normal
development. Thus, many of the known and unknown functions of BRCA1 may be mediated
independent of its ability to catalyze ubiquitination.
From a medical standpoint, the key function of BRCA1 is its ability to suppress tumor
formation in breast and ovarian tissues. Like BRCA1, many other oncoproteins and tumor
suppressors possess enzymatic activity. In most cases, the enzymatic function has proven to
be integral to the oncogenic process, and in some cases it can be targeted for therapeutic
gain, as illustrated by the clinical success of certain tyrosine kinase inhibitors. However,
because enzymatically inert Brca1 is sufficient to suppress tumor formation in several
settings (Fig. 1), including a model of human basal-like breast cancer, the E3 ligase activity
of BRCA1 appears to be dispensable for tumor suppression.
A role for the E3 ligase activity in BRCA1 tumor suppression was predicated partly on the
fact that this activity is ablated by certain tumor-associated lesions of the RING domain,
such as the C61G and C64G missense mutations (6). However, these mutations also disrupt
the interaction between BRCA1 and its partner protein BARD1 (5). Because mammary-
specific inactivation of either Brca1 or Bard1 elicits breast tumors with the same basal-like
phenotype (15), the tumor suppression activity of BRCA1 is probably mediated by the
BRCA1/BARD1 heterodimer. Unlike the tumorigenic C61G and C64G mutations, the
synthetic I26A mutation used in this study specifically ablates the enzymatic activity of
BRCA1 but allows proper assembly of the BRCA1/BARD1 heterodimer (7). Thus, the
tumorigenic RING mutations are likely to compromise BRCA1-mediated tumor suppression
primarily by impairing BRCA1/BARD1 heterodimerization.
The mouse model of hereditary breast cancer has provided meaningful insights into the
molecular mechanisms of BRCA1-mediated tumor suppression. First, the identical pattern
of breast carcinogenesis in conditional Brca1-, Bard1-, and Brca1/Bard1-null mice implies
that tumor suppression is dependent on the BRCA1/BARD1 heterodimer (15). Second, as
shown here tumor suppression does not require the E3 ligase activity of BRCA1/BARD1.
Third, our data also suggest that the ability of the BRCT domain to bind its phospho-ligands
is critical for BRCA1 tumor suppression. In light of this result, it is noteworthy that BRCA1/
BARD1 forms distinct protein complexes (A, B, and C) based on BRCT-mediated
interactions with three different repair proteins (Abraxas/CCDC98, BACH1/FancJ, and
CtIP) (1, 2). Because tumor suppression appears to be dependent on BRCA1 association
with one or more of these BRCT phospho-ligands (and/or others yet to be discovered), these
interactions may provide valuable targets for therapeutic intervention.
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Fig. 1.
The enzymatic activity of Brca1 is dispensable for tumor suppression. (A) Kaplan-Meier
tumor-free survival curves of KrasLSL-G12D/p53flex7/flex7/Pdx1-cre (KPC-Brca1+/+; black
curve; T50 = 68 days) mice compared with KrasLSL-G12D/p53flex7/flex7/Pdx1-cre/
Brca1flex2/flex2 (KPC-Brca1flex2/flex2; blue curve; T50 = 40 days; P < 0.0001) and
KrasLSL-G12D/p53flex7/flex7/Pdx1-cre/Brca1flex2/FH-I26A (KPC-Brca1flex2/FH-I26A; red curve;
T50 = 65 days; P = 0.2595) mice. (B) Kaplan-Meier survival curves of Brca1flex2/flex2/
Wapcre/+ (C-Brca1flex2/flex2; green curve; T50 = 512 days) females compared with
Brca1flex2/FH-I26A/Wapcre/+ (C-Brca1flex2/FH-I26A; red curve; P < 0.0001) females. (C)
Kaplan-Meier survival curves of p53LSL-R270H/+/Wapcre/+ (PC-Brca1+/+; black curve; T50 =
380 days) females compared with Brca1flex2/flex2/p53LSL-R270H/+/Wapcre/+ (PC-
Brca1flex2/flex2; blue curve; T50 = 309 days; P < 0.0001) and Brca1flex2/FH-I26A/
p53LSL-R270H/+/Wapcre/+ (PC-Brca1flex2/FH-I26A; red curve; T50 = 382 days; P = 0.5354)
females. (D) Kaplan-Meier survival curves of control Brca1FH-WT/FH-WT (black curve) mice
compared with Brca1tr/tr (blue curve; T50 = 529 days; P < 0.0001) and Brca1FH-I26A/FH-I26A
and Brca1FH-I26A/– (red curve; P = 0.5197) mice.
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Fig. 2.
The BRCT phospho-recognition property of Brca1 is critical for the DNA damage response.
(A) S1598F ablates the interaction between Bach1/FancJ and endogenous Brca1. MEFs
were prepared from mice with a knock-in allele (Bach1WT-FH) encoding wild-type Bach1
with C-terminal Flag-hemagglutinin (HA) epitopes. Bach1WT-FH and Brca1 levels were
examined by immunoblotting lysates of Brca1+/+/Bach1WT-FH/+ and Brca1S1598F/S1598F/
Bach1WT-FH/+ MEFs (left). To evaluate the Brca1/Bach1WT-FH interaction, lysates were
immunoprecipitated with a Brca1-specific antiserum or corresponding preimmune serum
(pre) and immunoblotted with HA-specific antibodies (right). The input (left) represents
2.5% of the protein amount used for immunoprecipitation (right). (B) Brca1S1598F/S1598F
cells are sensitive to genotoxic stress. ES cells proficient (Brca1+/− and Brca1S1598F/+) or
deficient (Brca1S1598F/S1598F) for BRCT phospho-recognition were examined for mitomycin
C (MMC) sensitivity in clonogenic survival assays, together with ES cells homozygous for
the hypomorphic Brca1Δ223-763 mutation. (C) BRCT phospho-recognition by Brca1 is
essential for homology-directed DNA repair. Brca1+/−, Brca1S1598F/S1598F, and
Brca1Δ223-763/Δ223-763 ES subclones containing the direct repeat–green fluorescent protein
(DR-GFP) substrate integrated into the Pim1 locus were transfected with either an I-SceI
expression vector or empty vector. I-SceI strongly induced the number of GFP-positive cells
in Brca1+/− cells (clone 4), indicating efficient homology-directed repair, but not in
Brca1S1598F/S1598F cells (clones 1 to 3). The reduction in GFP-positive cells in
Brca1S1598F/S1598F cells was similar to that of Brca1Δ223-763/Δ223-763 ES cells (clone 5),
which are known to be deficient in homology-directed repair (28).
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Fig. 3.
BRCT phospho-recognition is essential for Brca1 tumor suppression. (A) Kaplan-Meier
tumor-free survival curves of p53LSL-R270H/+/Wapcre/+ (PC-Brca1+/+; black curve; T50 =
380 days) females compared with Brca1flex2/flex2/p53LSL-R270H/+/Wapcre/+ (PC-
Brca1flex2/flex2; blue curve; T50 = 309 days; P < 0.0001) and Brca1flex2/S1598F/
p53LSL-R270H/+/Wapcre/+ (PC-Brca1flex2/S1598F; green curve; T50 = 308 days; P < 0.0001)
females. (B) Kaplan-Meier survival curves of KrasLSL-G12D/p53flex7/flex7/Pdx1-cre (KPC-
Brca1+/+; black curve; T50 = 68 days) mice compared with KrasLSL-G12D/p53flex7/flex7/Pdx1-
cre/Brca1flex2/flex2 (KPC-Brca1flex2/flex2; blue curve; T50 = 40 days; P < 0.0001) and
KrasLSL-G12D/p53flex7/flex7/Pdx1-cre/Brca1flex2/S1598F (KPC-Brca1flex2/S1598F; green curve;
T50 = 45 days; P < 0.0001) mice. (C) Kaplan-Meier survival curves of Brca1FH-WT/FH-WT
(black curve) mice compared with Brca1tr/tr (blue curve; P < 0.0001) and
Brca1S1598F/S1598F (green curve; P < 0.0001) mice.
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